Stock Watch: The Transatlantic Asymmetries Of Generic Drugs
Many Small-Molecule Generic Drug Dynamics Contrast Biosimilars
Investors love an opportunity to invest in a recovery play after the disclosure of bad news but, having lived in recent years under a succession of clouds, will generic drug companies begin to see biosimilars resurrect their sales growth?
You may also be interested in...
Viatris To Bring In Plenty Of Brand Knowledge With New CEO Smith
Only three months after joining Viatris’ board of directors, Scott Smith, famed for spearheading Celgene’s successful and lucrative Inflammation and Immunology division, has been announced as the company’s new CEO, beginning 1 April.
Teva Hopes For Revenue Growth For First Time Since 2017
The company’s new CEO Richard Francis is aiming for revenue growth this year; it would be the first time since 2017.
Dr Reddy’s Debuts Two Revlimid Exclusives As Part Of Complete Launch In US
Dr Reddy’s Laboratories is set to reap the rewards of a significant US generic launch – albeit one with a limited volume caveat decreed by a patent-litigation settlement deal – after it began selling its generic of Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid.